Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

GenAssist Raises “Millions of Dollars” for Novel Base Editing Drugs

publication date: Dec 8, 2022

Suzhou GenAssist Therapeutics raised “millions of dollars” in an A round to support its gene editing drugs that target neuromuscular diseases. Founded in 2020, the company owns global rights to TAM BE (Targeted AID-based Mutagenesis) base editing technology, which was discovered by one of its Founders, Xing Chang, PhD, who now serves as the company’s CSO. GenAssist is developing therapies for Duchenne Muscular Dystrophy (DMD) and Spinal Muscular Atrophy (SMA). The Series A financing was led by AstraZeneca-CCIG and included BV Baidu Ventures and Sequoia Capital. More details....

Share this with colleagues:  



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital